Publication | Closed Access
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2.5K
Citations
32
References
2011
Year
Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors. (Funded by Pfizer; ClinicalTrials.gov number, NCT00428597.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1